Abstract 1484
Background
Previous studies have identified several targetable oncogenic mutations in biliary tract cancer (BTC). However, reliable predictors of clinical response to therapeutic agents have not been established. This study aimed to identify predictors of clinical response to chemotherapy and immune checkpoint blockade in advanced BTC patients.
Methods
Genomic alterations in 54 patients with recurrent or metastatic BTC were investigated by targeted deep-sequencing for 524 key cancer genes using pre-treatment tumor tissues. The predictive value of genomic alterations, including mutational signatures, on response to chemotherapy and anti-PD-1/PD-L1 therapy, was assessed.
Results
Frequently altered genes included TP53 (50.0%), NOTCH1 (31.5%), KRAS (24.1%), KMT2C (22.2%), BAP1 (22.2%), and ERBB2 (22.2%). BAP1 deletion and NOTCH1 mutation were associated with a favorable response to chemotherapy. The homologous recombination deficiency (HRD)-associated signature (signature 3) was significantly higher in the responding patients to chemotherapy and a positive correlation between the HRD-signature and BAP1 deletion was observed, suggesting that HRD caused by BAP1 deletion may contribute to a favorable response to chemotherapy. A high proportion of signature 12 was associated with favorable overall and progression-free survival after chemotherapy. Among 19 patients treated with anti-PD-1/PDL1 therapy, the mismatch repair (MMR) deficiency–associated signatures (signatures 6, 15, 20, and 26) were significantly higher in the responding patients.
Conclusions
This study identified several predictors on therapeutic response of advanced BTC. BAP1 deletion and NOTCH1 mutation were predictors of a favorable response to chemotherapy. Furthermore, the mutational signatures associated with HRD and MMR significantly correlated with the response to chemotherapy and anti-PD-1/PD-L1 therapy, respectively.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National R&D Program for Cancer Control, Republic of Korea.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3222 - Nab-paclitaxel (Nab) plus Gemcitabine (G) is more effective than G alone in locally advanced, unresectable pancreatic cancer (LAUPC): the GAP trial, a GISCAD phase II comparative randomized trial.
Presenter: Stefano Cascinu
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
5184 - Perioperative FLOT + anti-PD-L1 avelumab (FLOT-A) chemo-immunotherapy in resectable oesophagogastric adenocarcinoma (OGA): safety and biomarker data from the ICONIC trial safety run-in
Presenter: Michael Davidson
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
4511 - POLO: Health-related quality of life (HRQoL) of olaparib maintenance treatment versus placebo in patients with a germline BRCA mutation and metastatic pancreatic cancer (mPC)
Presenter: Pascal Hammel
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
4623 - Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) versus best supportive care (BSC) in previously systemically treated patients (pts) with advanced hepatocellular carcinoma (HCC): KEYNOTE-240
Presenter: Philippe Merle
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
3561 - Comprehensive Genomic Profiling (CGP) of mixed hepatocellular cholangiocarcinomas (cHCC-CCA)
Presenter: Karthikeyan Murugesan
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
4537 - Outcomes based on plasma biomarkers for the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)
Presenter: Lorenza Rimassa
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
3521 - Large-scale analysis of CDH1 mutations define a distinctive molecular subset in gastric cancer (GC)
Presenter: Jingyuan Wang
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
1438 - Low-dose aspirin and risk of gastric and oesophageal cancer: a population-based study
Presenter: Luis Garcia Rodriguez
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
4638 - Health-Related Quality of Life (HRQoL) Impact of Pembrolizumab (P) Versus Chemotherapy (C) as First-Line (1L) Treatment in PD-L1–Positive Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Presenter: Eric Van Cutsem
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
5708 - Chemotherapy for Frail and Elderly Patients (pts) with Advanced Gastroesophageal Cancer (aGOAC): Quality of Life (QoL) results from the GO2 Phase III Trial
Presenter: Peter Hall
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract